Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Interleukin-18 receptor accessory protein (IL-18RAP), also known as IL-18 receptor beta, is a transmembrane protein that functions as the signaling subunit of the IL-18 receptor complex (UniProt, Q99467). While the IL-18 receptor alpha subunit (IL-18R1) provides the initial binding site for the IL-18 ligand, IL-18RAP is essential for forming a high-affinity heterotrimeric complex that initiates intracellular signaling (NCBI Gene, 8807). Upon ligand binding and recruitment of IL-18RAP, the complex activates the MyD88-dependent pathway, leading to the activation of NF-kappaB and mitogen-activated protein kinases (MAPK) (PubMed, 10653850). This signaling cascade is a primary driver for the production of interferon-gamma (IFN-gamma) in T cells and natural killer (NK) cells, which is critical for the Type 1 immune response (StatPearls, NBK545159). Dysregulation of IL-18RAP signaling is strongly associated with various inflammatory and autoimmune diseases, including Celiac disease, Crohn's disease, and rheumatoid arthritis. Therapeutic targeting of the IL-18/IL-18RAP axis is an active area of research, with drugs like Tadekinig alfa and GSK1070806 designed to neutralize the pathway's pro-inflammatory effects (, NCT03664037). Although most current clinical candidates target the IL-18 ligand, IL-18RAP remains a significant potential target for small molecules or antibodies aimed at disrupting the receptor complex assembly. The target's role in mediating chronic inflammation makes it a valuable focus for biotech analysts evaluating treatments for refractory autoimmune conditions.
Inhibition of the IL-18 signaling pathway by preventing the formation of the active IL-18/IL-18R1/IL-18RAP signaling complex.
2 more in the full profile.
Source types: Trial registry. Sources are available to Gosset users. Log in to see them.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Interleukin-18 receptor accessory protein (IL-18RAP) (IL-18RAP).